Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$58.99T
24h Vol:
$10.08B
Dominance:
MSFT:5.13%
Stocklytics Platform
BETA
Instrument logo  DXCM

DexCom Inc

DXCM
72 / 100
High Quality
S&P500
$115.32arrow_drop_down-0.73%-$0.85

Performance History

Stocklytics logo
Key Stats
Open$116.35
Prev. Close$116.26
EPS1.3
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$44.78B
PE Ratio89.36
LOWHIGH
Day Range115.85
118.19
52 Week Range74.75
139.55
Ratios
P/B Ratio21.67
Revenue$3.62B
Operating M. %20.97%
Earnings$541.50M
Earnings Growth %58.70%
EBITDA Margin %21.64%
ROE %25.78%
EPS1.3

Score Breakdown

72vs 53. Market Avg.

All Score 72 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

DXCMMARKET
Value3339
Quality7740
Ownership019
Growth5946
Dividends-37
warning

DexCom Inc's Price growth average in the last 3 years of 5.42% is modest compared to market average of 6.14%. This indicates DXCM could be a bad value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$771.91
24H (%)arrow_drop_up0.30%
24H ($)$2.38
MARKET CAP$733.45B
PRICE$525.32
24H (%)arrow_drop_down-0.36%
24H ($)-$1.91
MARKET CAP$485.88B
PRICE$160.78
24H (%)arrow_drop_down-0.64%
24H ($)-$1.05
MARKET CAP$387.30B
PRICE$128.84
24H (%)arrow_drop_down-0.47%
24H ($)-$0.61
MARKET CAP$326.48B

About DexCom Inc (DXCM)

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Sector
Healthcare
Industry
Medical Devices
CEO
Mr. Kevin Ronald Sayer
Headquarters
San Diego
Employees
7500
Exchange
NASDAQ
add DexCom Inc to watchlist

Keep an eye on DexCom Inc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
What is the 52-week high and low for DexCom Inc (DXCM)?

For DexCom Inc (DXCM), the 52-week high is $139.55, which is 20.13% from the current price. The 52-week low is $74.75, the current price is 55.41% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

question_mark
What is DexCom Inc's (DXCM) price per share?

The current price per share for DexCom Inc (DXCM) is $116.17. The stock has seen a price change of -$0.09 recently, indicating a -0.08% change. This reflects the stock's recent market performance and investor sentiment.

question_mark
Is DexCom Inc (DXCM) a growth stock?

DexCom Inc (DXCM) has shown an average price growth of 5.35% over the past three years. It has received a score of 64 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying DexCom Inc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

question_mark
What is DexCom Inc (DXCM) stock price performance year to date (YTD)?

As of the latest data, DexCom Inc (DXCM) has a year-to-date price change of -5.61%. Over the past month, the stock has experienced a price change of -6.5%. Over the last three months, the change has been 1.94%. Looking at a longer horizon, the five-year price change stands at 231.72%.

question_mark
Is DexCom Inc (DXCM) a profitable company?

DexCom Inc (DXCM) has a net income of $541.5M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 63.19% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 20.97% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $3.62B, with a revenue growth rate of 24.49%, providing insight into the company's sales performance and growth. The gross profit is $2.29B. Operating income is noted at $597.7M. Furthermore, the EBITDA is $916.7M.

question_mark
What is the market capitalization of DexCom Inc (DXCM)?

DexCom Inc (DXCM) has a market capitalization of $44.79B. The average daily trading volume is 3.7M, indicating the stock's liquidity and investor engagement.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.